Enumeral Biomedical (ENUM) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 12, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'Enumeral Biomedical Holdings, Inc.	'
Entity Central Index Key	'0001561551	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	51,591,710
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$13,191,884	$263,910
Marketable securities	3,017,324	'
Accounts receivable	70,408	125,000
Prepaid expenses and other current assets	129,908	142,741
Total current assets	16,409,524	531,651
Property and equipment, net	579,541	747,888
Other assets:	'	'
Restricted cash	32,666	32,666
Other assets	8,116	6,100
Total assets	17,029,847	1,318,305
Current liabilities:	'	'
Accounts payable ($78,271 and $109,740 due to related parties, respectively)	265,649	342,595
Accrued expenses and other current liabilities ($58,750 and $50,942 due to related parties, respectively)	446,877	206,035
Deferred rent	15,101	15,101
Deferred revenue	'	25,714
Current portion of long-term debt	'	716,000
Derivative liabilities	21,136,878	41,466
Total current liabilities	21,864,505	1,346,911
Deferred rent, net of current portion	25,890	37,267
Long-term debt, net of current portion and discount	'	339,348
Total liabilities	21,890,395	1,723,526
Commitments and contingencies	'	'
Stockholders' deficiency	'	'
Preferred stock, $.001 par value; 10,000,000 shares authorized: -0- shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	'	'
Common stock, $.001 par value; 300,000,000 shares authorized: 51,591,710 and 16,692,093 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	51,592	16,692
Additional paid-in-capital	15,819,494	9,089,324
Accumulated defict	-20,731,634	-9,511,237
Total stockholders' deficiency	-4,860,548	-405,221
Total liabilities and stockholders' deficiency	$17,029,847	$1,318,305

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Condensed Consolidated Balance Sheets [Abstract]	'	'
Accounts payable, related parties	$78,271	$109,740
Accrued expenses and other current liabilities, related parties	$58,750	$50,942
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	51,591,710	16,692,093
Common stock, shares outstanding	51,591,710	16,692,093

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Collaboration and license revenues	$65,000	$90,881	$115,714	$158,048
Grant revenue	5,408	49,959	5,408	182,996
Total revenues	70,408	140,840	121,122	341,044
Cost of revenue and expenses:	'	'	'	'
Research and development	1,058,711	583,372	2,535,228	1,749,775
General and administrative	1,163,218	495,246	2,009,918	1,198,531
Total cost of revenue and expenses	2,221,929	1,078,618	4,545,146	2,948,306
Loss from operations	-2,151,521	-937,778	-4,424,024	-2,607,262
Other income (expense):	'	'	'	'
Interest expense	-140,917	-25,145	-268,998	-84,077
Other expense	-1,693,747	'	-1,693,747	'
Change in fair value of derivative liabilities	-4,837,307	621	-4,833,628	789
Total other income (expense), net	-6,671,971	-24,524	-6,796,373	-83,288
Net loss before income taxes	-8,823,492	-962,302	-11,220,397	-2,690,550
Provision for income taxes	'	'	'	'
Net loss	($8,823,492)	($962,302)	($11,220,397)	($2,690,550)
Net loss per share - basic and diluted (in dollars per share)	($0.22)	($0.07)	($0.44)	($0.21)
Weighted-average number of common shares attributable to common stockholders - basic and diluted (in shares)	40,724,549	14,056,056	25,462,496	12,861,797

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholders' Deficiency (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Balance	'	($405,221)
Balance, shares	'	16,692,093
Stock-based compensation expense	'	510,587
Conversion of convertible promissory notes and accrued interest, net of debt discount associated with warrants	'	687,654
Conversion of convertible promissory notes and accrued interest, net of debt discount associated with warrants (in shares)	'	3,230,869
Proceeds from issuance of common stock in PPO, net of issuance costs	'	18,255,447
Derivative liability for warrants issued in PPO and to placement Agent	'	-16,261,784
Shares issued to placement agents	'	'
Recapitalization for reverse merger	'	'
Exchange of Series B convertible preferred stock into common stock	'	1,597,860
Issuance of common stock to pre-merger share holders	'	1,693,747
Beneficial conversion feature and warrant associated with convertible promissory note	'	281,559
Net loss	-8,823,492	-11,220,397
Balance	-4,860,548	-4,860,548
Balance, shares	51,591,710	51,591,710
Common Stock [Member]	'	'
Balance	'	16,692
Balance, shares	'	16,692,093
Stock-based compensation expense	'	'
Conversion of convertible promissory notes and accrued interest, net of debt discount associated with warrants	'	3,231
Conversion of convertible promissory notes and accrued interest, net of debt discount associated with warrants (in shares)	'	3,230,869
Proceeds from issuance of common stock in PPO, net of issuance costs	'	21,549
Proceeds from issuance of common stock in PPO, net of issuance costs (in shares)	'	21,549,510
Derivative liability for warrants issued in PPO and to placement Agent	'	'
Shares issued to placement agents	'	150
Shares issued to placement agents (in shares)	'	150,000
Recapitalization for reverse merger	'	5,498
Recapitalization for reverse merger (in shares)	'	5,497,804
Exchange of Series B convertible preferred stock into common stock	'	2,778
Exchange of Series B convertible preferred stock into common stock (in shares)	'	2,777,687
Issuance of common stock to pre-merger share holders	'	1,694
Issuance of common stock to pre-merger share holders (in shares)	'	1,693,747
Beneficial conversion feature and warrant associated with convertible promissory note	'	'
Net loss	'	'
Balance	51,592	51,592
Balance, shares	51,591,710	51,591,710
Additional Paid-In Capital [Member]	'	'
Balance	'	9,089,324
Stock-based compensation expense	'	510,587
Conversion of convertible promissory notes and accrued interest, net of debt discount associated with warrants	'	684,423
Proceeds from issuance of common stock in PPO, net of issuance costs	'	18,233,898
Derivative liability for warrants issued in PPO and to placement Agent	'	-16,261,784
Shares issued to placement agents	'	-150
Recapitalization for reverse merger	'	-5,498
Exchange of Series B convertible preferred stock into common stock	'	1,595,082
Issuance of common stock to pre-merger share holders	'	1,692,053
Beneficial conversion feature and warrant associated with convertible promissory note	'	281,559
Net loss	'	'
Balance	15,819,494	15,819,494
Accumulated Deficit [Member]	'	'
Balance	'	-9,511,237
Stock-based compensation expense	'	'
Conversion of convertible promissory notes and accrued interest, net of debt discount associated with warrants	'	'
Proceeds from issuance of common stock in PPO, net of issuance costs	'	'
Derivative liability for warrants issued in PPO and to placement Agent	'	'
Shares issued to placement agents	'	'
Recapitalization for reverse merger	'	'
Exchange of Series B convertible preferred stock into common stock	'	'
Issuance of common stock to pre-merger share holders	'	'
Beneficial conversion feature and warrant associated with convertible promissory note	'	'
Net loss	'	-11,220,397
Balance	($20,731,634)	($20,731,634)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($11,220,397)	($2,690,550)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and Amortization	212,514	209,147
Stock-based compensation	510,587	159,754
Change in fair value of derivatives	4,833,628	-789
Non-cash costs associated with reverse merger	1,693,747	'
Accretion of debt discount	177,712	4,960
Changes in operating assets and liabilities:	'	'
Accounts receivables	54,592	-33,791
Prepaid expenses and other assets	10,817	20,253
Accounts payable	-76,946	-160,463
Accrued expenses and other current liabilities	282,342	74,249
Deferred rent	-11,377	-7,791
Deferred revenue	-25,714	-15,122
Net cash used in operating activities	-3,558,495	-2,440,143
Cash flows from investing activities:	'	'
Purchases of property and equipment	-44,167	-54,271
Purchase of marketable securities	-3,017,324	'
Net cash used in investing activities	-3,061,491	-54,271
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock in PPO, net of issuance costs	18,255,448	'
Proceeds from issuance of convertible promisory note	750,000	'
Payments on Long-term debt	-1,055,348	-537,000
Net cash provided by financing activities	19,547,960	2,033,902
Net Increase (decrease) in cash and cash equivalents	12,927,974	-460,512
Cash and cash equivalents, beginning of period	263,910	1,747,534
Cash and cash equivalents, end of period	13,191,884	1,287,022
Supplemental cash flow disclosures:	'	'
Cash paid for interest	73,977	79,147
Conversion of convertible note and accrued interest, net of debt discount associated with warrants	687,654	'
Series A-2 convertible preferred stock [Member]	'	'
Cash flows from financing activities:	'	'
Proceeds from issuance of convertible preferred stock, net of issuance costs	'	2,570,902
Series B convertible preferred stock [Member]	'	'
Cash flows from financing activities:	'	'
Proceeds from issuance of convertible preferred stock, net of issuance costs	$1,597,860	'

NATURE_OF_BUSINESS

NATURE OF BUSINESS	9 Months Ended
	Sep. 30, 2014
NATURE OF BUSINESS [Abstract]	'
NATURE OF BUSINESS	'
	1 - NATURE OF BUSINESS
	Enumeral Biomedical Corp. (“Enumeral”) was founded in 2009 in the state of Delaware as Enumeral Technologies, Inc. The name was later changed to Enumeral Biomedical Corporation.
	On July 31, 2014 (the “Closing Date”), Enumeral entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Enumeral Biomedical Holdings, Inc., which was formerly known as Cerulean Group, Inc. (“Enumeral Biomedical” or the “Company”), and Enumeral Acquisition Corp., a wholly owned subsidiary of Enumeral Biomedical (“Acquisition Sub”), pursuant to which the Acquisition Sub merged with and into Enumeral (the “Merger”). Enumeral was the surviving corporation in the Merger and became a wholly owned subsidiary of the Company.
	As a result of the Merger, all issued and outstanding common and preferred shares of Enumeral were exchanged for common shares of Enumeral Biomedical Holdings, Inc. The Merger is considered to be a recapitalization of the Company which has been retrospectively applied to these financial statements for all periods presented.
	Upon the closing of the Merger and under the terms of a split-off agreement and a general release agreement (the “Split-Off Agreement”), the Company transferred all of its pre-Merger operating assets and liabilities to its wholly-owned special-purpose subsidiary, Cerulean Operating Corp. (the “Split-Off Subsidiary”). Thereafter, pursuant to the Split-Off Agreement, the Company transferred all of the outstanding shares of capital stock of Split-Off Subsidiary to the pre-Merger majority stockholder of the Company, and the former sole officer and director of the Company (the “Split-Off”), in consideration of and in exchange for (i) the surrender and cancellation of an aggregate of 23,100,000 shares of the Company's common stock held by such stockholder (which were cancelled and will resume the status of authorized but unissued shares of the Company's common Stock) and (ii) certain representations, covenants and indemnities.
	As a result of the Merger and Split-Off, the Company discontinued its pre-Merger business and acquired the business of Enumeral, and will continue the existing business operations of Enumeral as a publicly-traded company under the name Enumeral Biomedical Holdings, Inc.
	Following the Merger, the Company is discovering and developing novel antibody therapeutics that help the immune system attack diseased cells (“immunomodulators”). The Company believes it has a unique ability to extensively interrogate cells of the human immune system for drug candidate validation, and that this ability could give the Company a distinct advantage in selecting potential best-in-class candidates. The Company is building a pipeline of drug candidates for the treatment of cancer, infectious, and inflammatory diseases and leveraging the breadth of the Company's technology in order to drive near-term cash flows from out-licensing of the Company's drug candidates and through strategic collaboration partnerships. The Company's near-term goals include performance of preclinical testing on drug candidates resulting from internal programs to generate data to support the Company's ability to obtain revenue from co-development partners. The Company has focused its research efforts on using its proprietary drug discovery platform utilizing, in part, technology licensed by Enumeral from M.I.T., Harvard University and other institutions to identify and elucidate antibodies and antigens that are responsible for diseases that affect millions of individuals and are underserved by current therapeutic alternatives. These diseases have included cancer, infectious, and inflammatory diseases. The Company believes that the breadth of the drug discovery platform offers the potential to grow through revenue-generating collaborative research and development partnerships.
	On July 31, 2014, the Company changed its fiscal year end from October 31 to December 31.

RISK_AND_UNCERTAINTIES

RISK AND UNCERTAINTIES	9 Months Ended
	Sep. 30, 2014
RISK AND UNCERTAINTIES [Abstract]	'
RISK AND UNCERTAINTIES	'
	2 - RISK AND UNCERTAINTIES
	The Company is subject to a number of risks common to emerging companies in the life sciences industry. Principal among these risks are the uncertainties of the drug development process, technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company's competitors, protection of proprietary technology, compliance with government regulations and approval requirements, uncertainty of market acceptance of products, product liability, and the need to obtain financing necessary to fund future operations.
	As of September 30, 2014, the Company has a working capital deficiency of $5,454,981 due to $21,136,878 of derivative liabilities, and an accumulated deficit of $20,731,634. Additionally, the Company has incurred negative cash flows from operations and net losses to date. The Company is in the process of completing corporate collaborations to gain market acceptance of its technology and increase revenues. In connection with the Merger, the Company raised $21.5 million of gross proceeds, prior to the deduction of expenses related to the transaction.
	In view of these matters, continuation as a going concern is dependent upon the continued operations of the Company, which in turn is dependent upon the Company's ability to meet its financial requirements, raise additional capital, and the success of its future operations. The Company believes that its existing cash and cash equivalents at September 30, 2014 will be sufficient to fund its operations for at least the next 12 months.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Recently Adopted Accounting Standards
	On June 10, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) – Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”), which eliminates the concept of a development stage entity in its entirety from current accounting guidance. Amendments to the consolidation guidance may result in more DSEs being considered variable interest entities. The new guidance applies to all entities that previously met the definition of a DSE. ASU 2014-10 is effective for public business entities for annual reporting periods beginning after December 15, 2015, and interim periods therein. Early adoption of the new standard is permitted. Management has elected to early adopt ASU 2014-10, as permitted and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the Company's 2013 financial statements for the year ended December 31, 2013, which are included in the Company's Form 8-K for the Merger occurring on July 31, 2014, as discussed above.
	The preparation of financial statements in conformity with these accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and the reported amounts of expenses during the reported period. Ultimate results could differ from the estimates of management.
	In the opinion of management, the unaudited financial statements included herein contain all adjustments necessary to present fairly the Company's financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2014 may not be indicative of results for the full year.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reported period. Significant estimates used in preparing the Company's financial statements include the estimation of stock based compensation, stock warrants liability, accrued expenses, revenue recognition and income taxes. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of 90 days or less from the purchase date to be cash equivalents. Cash and cash equivalents are held in depository and money market accounts and are reported at fair value.
	Marketable securities consist of U.S. treasury securities with maturities of more than 90 days. The Company has determined the appropriate balance sheet classification of the securities as current since they are available for use in current operating activities, regardless of actual maturity dates, and are recorded on the balance sheet at fair value.
	Concentration of Credit Risk
	The Company has no significant off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements. Financial instruments that subject the Company to credit risk consists primarily of cash and cash equivalents. The Company generally invests its cash in money market funds, U.S. Treasury securities and U.S. Agency securities that are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. At times, the Company's cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
	Fair Value of Financial Instruments
	Fair values of financial instruments included in current assets and current liabilities are estimated to approximate their book values, due to the short maturity of such instruments. All debt was based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value. The Company's assets and liabilities that are measured at fair value on a recurring basis are measured in accordance with FASB's Accounting Standards Codification 820, Fair Value Measurements and Disclosures, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements.
	The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:
		•	Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets in active markets.
		•	Level 2: Inputs to the valuation methodology included quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
		•	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The Company's cash equivalents carried at fair value are primarily comprised of investments in a U.S. Treasury and federal agency backed money market fund. The valuation of the Company's derivative liabilities is discussed below and in Note 9.
	The following table presents information about the Company's financial assets and liabilities measured at a fair value on a recurring basis as of September 30, 2014 and December 31, 2013:
			September 30,		Quoted Prices in		Observable		Unobservable
			2014		Active Markets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets
	Cash		$	1,219,603	$	1,219,603	$	-	$	-
	Money Market funds, included in cash equivalents		$	11,972,281	$	11,972,281	$	-	$	-
	Marketable securities – U.S. Treasuries		$	3,017,324	$	3,017,324	$	-	$	-
	Liabilities
	Derivative liabilities		$	21,136,878	$	-	$	-	$	21,136,878
			December 31,		Quoted Prices		Observable		Unobservable
			2013		in Active		Inputs		Inputs
					Markets		(Level 2)		(Level 3)
					(Level 1)
	Assets
	Cash and cash equivalents		$	263,910	$	263,910	$	-	$	-
	Liabilities
	Derivative liabilities		$	41,466	$	-	$	-	$	41,466
	The following table provides a roll forward of the fair value of the Company's warrant liabilities, using Level 3 inputs:
	Balance at December 31, 2013		$	41,466
	Warrants granted with PPO at July 31, 2014			16,261,784
	Change in fair value			4,833,628
	Balance at September 30, 2014		$	21,136,878
	Accounts Receivable and Allowance for Doubtful Accounts
	Trade receivables are recorded at the invoiced amount. The Company maintains allowances for doubtful accounts, if needed, for estimated losses resulting from the inability of customers to make required payments. This allowance is based on specific customer account reviews and historical collections experience. There was no allowance for doubtful accounts as of September 30, 2014 or December 31, 2013.
	Property and Equipment
	Property and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation is provided using the straight-line method over the estimated useful lives of the assets as follows:
	Lab equipment		5 years
	Computer equipment and software		3 years
	Furniture		3 years
	Leasehold improvements		Shorter of useful life or life of the lease
	Impairment of Long-Lived Assets
	Long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicated that there is impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. There have been no impairments recognized during the nine months ended September 30, 2014 and 2013, respectively.
	Revenue Recognition
	Collaboration and license revenue
	Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured and the Company has no further performance obligations under the license agreement. Multiple element arrangements, such as license and development arrangements are analyzed to determine whether the deliverables, which often include license and performance obligations such as research and steering committee services, can be separated or whether they must be accounted for as a single unit of accounting in accordance with GAAP. The Company recognizes up-front license payments as revenue upon delivery of the license only if the license has stand-alone value and the fair value of the undelivered performance obligations, typically including research and/or steering committee services, can be determined. If the fair value of the undelivered performance obligations can be determined, such obligations would then be accounted for separately as performed. If the license is considered to either (i) not have stand-alone or (ii) have stand-alone value but the fair value of any of the undelivered performance obligations cannot be determined, the arrangement would then be accounted for as a single unit of accounting and the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed.
	Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized. Revenue will be recognized using either a relative performance or straight-line method. The Company recognizes revenue using the relative performance method provided that the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and such performance obligations are provided on a best-efforts basis. Direct labor hours or full-time equivalents are typically used as a measure of performance. Revenue recognized under the relative performance method would be determined by multiplying the total payments under the contract, excluding royalties and payments contingent upon achievement of substantive milestones, by the ratio of level of effort incurred to date to estimated total level of effort required to complete the Company's performance obligations under the arrangement. Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the relative performance method, as of each reporting period.
	If the Company cannot reasonably estimate the level of effort required to complete its performance obligations under an arrangement, the performance obligations are provided on best-efforts basis and the Company can reasonably estimate when the performance obligation ceases or the remaining obligations become inconsequential and perfunctory. At that time, the total payments under the arrangement, excluding royalties and payments contingent upon achievement of substantive milestones, would be recognized as revenue on a straight-line basis over a period the Company expects to complete its performance obligations.
	Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line basis, as of the period ending date.
	The difference between the total consideration received to date and the revenue recognized is recorded as deferred collaboration revenue and totals $0 and $25,714 at September 30, 2014 and December 31, 2013, respectively.
	Grant Revenue
	The Company recognizes nonrefundable grant revenue that is earned in connection with its Research Agreement with the National Cancer Institute (“NCI”). Grant revenue consists of a portion of the funds received to date by the NCI, which allow the Company to conduct research on colon cancer tissues. Revenue is recognized as the related research services are performed in accordance with the terms of the agreement. The difference between the total consideration received to date and the revenue recognized is recorded as deferred grant revenue and totals $0 at both September 30, 2014 and December 31, 2013. In September 2014, the Company was awarded a Phase II Small Business Innovation Research contract from NCI.
Research and Development Expenses
Research and development expenditures are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, clinical supply costs, contract services, depreciation and amortization expense and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred. Legal fees incurred in connection with patent applications, along with fees associated with the license to the Company's core technology, are expensed as research and development expense.
Derivative Liabilities
The Company's derivative liabilities relates to (a) warrants to purchase an aggregate of 23,549,510 shares of the Company's common stock that were issued in connection with the July 2014 PPO (as defined below in Note 8) and (b) warrants to purchase 41,659 shares of Enumeral Series A Preferred Stock that were issued in December 2011 and June 2012 pursuant to Enumeral's debt financing arrangement with Square 1 Bank (as further described in Note 5) that were subsequently converted into warrants to purchase 66,574 shares of the Company's common stock in connection with the July 2014 Merger. Additional detail regarding these warrants can be found in Note 9 below.
Due to the price protection provision included in the warrant agreements, the warrants were deemed to be liabilities and, therefore, the fair value of the warrants is recorded in the current liability section of the balance sheet. As such, the outstanding warrants are revalued each reporting period with the resulting gains and losses recorded as the change in fair value of warrant liability on the statement of operations.
The Company used the Black-Scholes option-pricing model to estimate the fair values of the issued and outstanding warrants upon issuance and as of September 30, 2014.
Stock-Based Compensation
The Company has elected to use the Black-Scholes option pricing model to determine the grant date fair value of share-based awards. The Company recognizes the compensation cost of employee share-based awards on a straight-line basis over the employee's requisite service period of each award, which is generally the vesting period.
The fair value of the restricted stock awards granted to employees is based upon the fair value of the common stock on the date of grant. Expense is recognized over the vesting period.
The Company has recorded stock-based compensation expense of $510,587 and $159,754 for the nine months ended September 30, 2014 and 2013, respectively, and $304,163 and $79,771 for three months ended September 30, 2014 and 2013, respectively. The Company has an aggregate of $953,653 of unrecognized stock-based compensation cost as of September 30, 2014 to be amortized over a weighted average period of 1.72 years.
Prior to the Merger, Enumeral engaged a third party to develop an estimate of the fair value of a share of Enumeral's common stock on a fully-diluted, minority, non-marketable basis as of December 31, 2013. Based upon unaudited historical, pro-forma and/or forecast financial and operational information, which Enumeral management represented as accurately reflecting the company's operating results and financial position, the third party utilized both a market approach (using various financial statement metrics of similar enterprises' equity securities to estimate the fair value of Enumeral's equity securities) and an income approach (which bases value on expectations of future income and cash flows) in their analyses. The fair value of a single share of common stock was determined using the option pricing method, which treats common and preferred stock as call options on the aggregate enterprise value and using traditional models, including Black-Scholes or binomial models, to calculate share values.
During the quarter ended September 30, 2014, the Company engaged a third party to develop a binomial lattice model to estimate the fair value of options to purchase a total of 450,000 shares with vesting based on the future performance of a share of the Company's common stock.
Following the Merger, the Company's common stock became publicly traded, and fair market value is determined based on the closing sales price of the Company's common stock on the OTC Markets.
Earnings (Loss) Per Share
Basic earnings (loss) per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of September 30, 2014 and December 31, 2013. At September 30, 2014 and December 31, 2013, the number of shares underlying options and warrants that were anti-dilutive was approximately 27.2 million shares and 0.9 million shares, respectively.
Income Taxes
The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company's financial statements contain certain deferred tax assets, which have arisen primarily as a result of operating losses, as well as other temporary differences between financial and tax accounting. The Company would establish a valuation allowance if the likelihood of realization of the deferred tax assets is reduced based on an evaluation of objective verifiable evidence. Significant management judgment is required in determining the Company's provision for income taxes, the Company's deferred tax assets and liabilities and any valuation allowance recorded against those net deferred assets. The Company evaluates the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized.
The Company accounts for uncertain tax positions in accordance with GAAP and has no uncertain tax liabilities at September 30, 2014 or December 31, 2013. The guidance requires the Company to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authority. If a tax position meets the more likely than not recognition criteria, the guidance requires the tax position be measured at the largest amount of benefit greater than 50% likely of being realized upon ultimate settlement.
New Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”). ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in ASU 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to illustrate the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization's contracts with customers. ASU 2014-09 is effective retrospectively for fiscal years, and interim periods within those years beginning after December 15, 2016 for public companies and 2017 for non-public entities. Management is evaluating the effect, if any, on the Company's financial position and results of operations.
In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation – Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for annual periods and interim periods within those periods beginning after December 31, 2015. Earlier adoption is permitted. The Company does not expect the adoption of this guidance will have a significant impact on the Company's consolidated financial statements.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2014
PROPERTY AND EQUIPMENT [Abstract]	'
PROPERTY AND EQUIPMENT	'
	4 - PROPERTY AND EQUIPMENT
	Property and equipment, net consist of the following:
		September 30,			December 31,
		2014			2013
	Laboratory equipment	$	1,113,513		$	1,082,438
	Computer/office equipment and software		100,655			87,563
	Furniture, fixtures and office equipment		18,772			18,772
	Leasehold improvements		112,507			112,507
			1,345,447			1,301,280
	Less - Accumulated depreciation and amortization		(765,906	)		(553,392	)
		$	579,541		$	747,888
	Depreciation and amortization expense for the nine months ended September 30, 2014 and 2013 were $212,514 and $209,147, respectively, and, for the three months ended September 30, 2014 and 2013 were $70,985 and $71,752, respectively.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2014
DEBT [Abstract]	'
DEBT	'
	5 – DEBT
	Square 1 Financing and Security Agreement
	In December 2011, Enumeral entered into a $1.79 million venture debt financing with Square 1 Bank (as subsequently amended, the “Square 1 Financing”), pursuant to which Enumeral was required to comply with certain covenants on an annual basis. Enumeral was required to meet a maximum cash burn or liquidity ratio as indicated in the term loan agreement. In February 2014, Enumeral revised the terms of its Loan and Security Agreement with Square 1 Bank, whereby Enumeral agreed to complete an equity financing for gross cash proceeds of $2.0 million by March 31, 2014 and $4.0 million by June 30, 2014. Additionally, beginning on the date that Enumeral completed an equity financing for gross cash proceeds of $2.0 million, a monthly minimum unrestricted cash balance was required based upon three times the trailing three month cash burn.
	In June 2014, Enumeral further revised the terms of its Loan and Security Agreement with Square 1 Bank, whereby Enumeral extended its deadline to complete an equity financing for gross cash proceeds of $4.0 million to August 1, 2014. Additionally, Enumeral amended its minimum cash requirement beginning June 26, 2014 through August 1, 2014, pursuant to which Enumeral was required to maintain a minimum of $300,000 in unrestricted cash.
	In August 2014, Enumeral fully repaid this loan.
	In connection with the Square 1 Financing, Enumeral issued warrants to purchase an aggregate of 41,659 shares of Enumeral Series A preferred stock that were subsequently converted into warrants to purchase 66,574 shares of the Company's common stock in connection with the July 2014 Merger, as further described in Note 9 below.
	Convertible Promissory Notes
	In February 2014, Enumeral raised $750,000 by issuing convertible promissory notes at 12% interest per annum. The maturity date was July 2015. The holders of these notes had the right to convert the notes into shares of common stock at a conversion price of $0.27 per share. In July 2014, the principal of $750,000 and accrued interest of $41,500, offset by $103,846 of debt discount, related to these notes were converted into 3,230,869 shares of common stock (see Note 8). If prior to maturity or conversion, Enumeral consummated a liquidation event as defined, at the election of the holder, (a) Enumeral would have been required to pay the holders an amount equal to the sum of three times the total principal amount then outstanding under these notes, plus all accrued and unpaid interest due, (b) the outstanding principal of the notes would have automatically converted into shares of Enumeral's Series A-2 Preferred Stock at the closing of the liquidation event at the Series A-2 Original Issue Price, and (c) the outstanding principal of the notes would have automatically converted into shares of Enumeral's common stock at the closing of the liquidation event at a price per share of $0.27.
	Enumeral allocated proceeds to the convertible notes and the warrants based upon the relative fair value on the issuance date which resulted in a $140,779 debt discount on the convertible promissory notes and $140,778 allocated to the warrants, recorded in equity. The allocation of proceeds to the warrants gave rise to a beneficial conversion feature which was recorded at the intrinsic value ($140,779) calculated as the difference between the adjusted conversion price of approximately $0.22 and the estimated fair value of Enumeral's common stock of $0.27. For the nine months ended September 30, 2014, the Company recorded $177,712 to interest expense as it relates to the beneficial conversion feature and debt discount associated with warrants.

COMMITMENTS

COMMITMENTS	9 Months Ended
	Sep. 30, 2014
COMMITMENTS [Abstract]	'
COMMITMENTS	'
	6 - COMMITMENTS
	Operating Leases
	In October 2012, the Company entered into a 37 month operating lease for office and research space consisting of 4,782 square feet in Cambridge, Massachusetts. The term of the lease expires on November 30, 2015. Enumeral maintains a security deposit relating to the facility, recorded as restricted cash on the accompanying balance sheet.
	Total rent expense was $231,084 and $216,778 for the nine months ended September 30, 2014 and 2013, respectively, and $78,017 and $75,544 for the three months ended September 30, 2014 and 2013, respectively.
	Future operating lease commitments as of September 30, 2014 are as follows:
	Year Ending December 31,
	2014	$	62,166
	2015		228,919
		$	291,085
	On November 7, 2014, the Company entered into a Indenture of Lease (the “Lease”) with King 200 CPD LLC, pursuant to which the Company will lease 16,825 square feet of office and laboratory space located at 200 CambridgePark Drive in Cambridge, Massachusetts for a term of 5 years. For further information on the Lease, please see Note 11 – Subsequent Event.
	Employment Agreements
	The Company has employment agreements with members of management which contain minimum annual salaries and severance benefits if terminated prior to the term of the agreements.

LICENSE_AGREEMENT_AND_RELATEDP

LICENSE AGREEMENT AND RELATED-PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
LICENSE AGREEMENT AND RELATED-PARTY TRANSACTIONS [Abstract]	'
LICENSE AGREEMENT AND RELATED-PARTY TRANSACTIONS	'
	7 – LICENSE AGREEMENT AND RELATED-PARTY TRANSACTIONS
	License Agreement
	In April 2011, Enumeral licensed certain intellectual property from the Massachusetts Institute of Technology (“MIT”), a related party pursuant to an Exclusive License Agreement (the “License Agreement”), in exchange for the payment of upfront license fees and a commitment to pay annual license fees, patent costs, milestone payments, royalties on sublicense income and, upon product commercialization, royalties on the sales of products covered by the licenses or income from corporate partners and the issuance of 66,303 shares of Enumeral common stock.
	All amounts paid related to the license fees have been expensed as research and development by Enumeral as incurred. The Company incurred $18,750 and $14,959 in the nine months ended September 30, 2014 and 2013, respectively, and $6,250 and $5,041 in the three months ended September 30, 2014 and 2013, respectively.
	In addition to potential future royalty and milestone payments that Enumeral may have to pay MIT per the terms of the License Agreement, Enumeral is obligated to pay an annual fee of $25,000 in 2014, $30,000 in 2015, $40,000 in 2016, and $50,000 every year thereafter unless the License Agreement is terminated. To date, no milestone payments have been made. No royalty payments have been payable as Enumeral has not commercialized any products as set forth in the License Agreement. Enumeral reimburses the costs to MIT and Harvard University for the continued prosecution of the licensed patent estate. For the nine months ended September 30, 2014 and 2013, Enumeral paid $399,388 and $157,611 for MIT and $114,217 and $26,629 for Harvard, respectively. For the three months ended September 30, 2014 and 2013, Enumeral paid $275,499 and $8,440 for MIT and $13,435 and $9,620 for Harvard, respectively.
	As of the effective date of the License Agreement through the date upon which $7,500,000 of funding for Enumeral's capital stock has been achieved, Enumeral is required to issue MIT and affiliates an aggregate amount of shares equaling 3% of Enumeral's issued and outstanding common stock on a fully diluted basis. In March 2013, Enumeral and MIT amended the License Agreement to clarify how equity issuances are to be made under the terms of the License Agreement. In April of 2013, Enumeral satisfied the $7,500,000 funding requirement through the Series A-2 financing which fulfilled the provision in the License Agreement that required Enumeral to issue shares to MIT and other licensing institutions set forth in the License Agreement. During 2013, Enumeral issued 146,406 shares of Enumeral common stock under this provision of the License Agreement. During the three months and nine months ended September 30, 2013, the Company incurred stock based compensation expense related to these additional shares in the amount of $12,274 and $35,875, respectively.
	The License Agreement also contained a provision whereby after the $7,500,000 funding requirement is met, MIT and other licensing institutions set forth in the License Agreement have a right to participate in certain future equity issuances by Enumeral. In addition, pursuant to that provision Enumeral may have to issue additional shares to MIT and other licensing institutions set forth in the License Agreement if Enumeral issues common stock at a price per share that is less than the fair market value per share of the common stock issued to MIT and such licensing institutions based upon a weighted average formula set forth in the License Agreement. In July 2014, Enumeral and MIT entered into a second amendment to the License Agreement, pursuant to which MIT's participation rights and anti-dilution rights under the license agreement were terminated. Other than the exchange of Enumeral's common stock for the Company's common stock in connection with the Merger, the Company did not issue any shares of common stock to MIT and such other licensing institutions in connection with the License Agreement in 2014.
	Consulting Agreements
	On April 19, 2011, Enumeral entered into a consulting agreement with Barry Buckland, Ph.D., a member of the board of directors. Pursuant to the original agreement, Dr. Buckland was be compensated through the issuance of 159,045 restricted common shares that vested on the following schedule: 25% on the execution of the contract, 25% on April 19, 2012 and the remaining 50% vesting in equal monthly installments through April 1, 2014. The term of the consulting agreement was three years. On February 11, 2013, the consulting agreement was amended so that Dr. Buckland would receive $75,000 per year for a period of one year. On August 14, 2013, the consulting agreement was amended so that Dr. Buckland would receive $37,500 per year for a period of one year. During the nine months ended September 30, 2014 and 2013, Enumeral recognized $15,209 and $52,989 of expense related to the consulting agreement, respectively, and during the three months ended September 30, 2014 and 2013, Enumeral recognized $12,500 and $10,827 of expense related to the consulting agreement, respectively. In September 2014, the Company and Dr. Buckland entered into a Scientific Advisory Board Agreement (the “SAB Agreement”) pursuant to which Dr. Buckland will serve as chairman of the Company's Scientific Advisory Board. The SAB Agreement has a term of two years. Pursuant to the terms of the SAB Agreement, Dr. Buckland will receive compensation on an hourly or per diem basis, either in cash or, at Dr. Buckland's election, in options to purchase the Company's common stock. The SAB Agreement limits the total amount of compensation payable to Dr. Buckland at $100,000 over any rolling 12-month period.
	On September 20, 2013, Enumeral entered into a consulting agreement with Allan Rothstein and Norman Rothstein (collectively the “consultants”). Pursuant to the consulting agreement, Allan Rothstein was elected as a member of the Board of Directors of Enumeral. The consultants were compensated through the issuance of 1,000,000 shares of restricted common stock of Enumeral with one third vesting upon the execution of the consulting agreement, one third vesting on December 10, 2013 and one third vesting on March 10, 2014. The consulting agreement has a term of two years. During the three and nine months ended September 30, 2014, Enumeral recognized $0 and $68,764 of expense related to the consulting agreement, respectively. This consulting agreement was terminated on July 30, 2014.

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2014
EQUITY [Abstract]	'
EQUITY	'
	8 – EQUITY
	Common Stock
	On April 8, 2014, Enumeral amended its articles of incorporation to increase the number of authorized shares of common stock from 15,000,000 to 24,000,000.
	In April 2014, Enumeral issued 948,823 shares of Series B Convertible Preferred Stock at an issue price of $2.125 per share for proceeds of $1,597,860, net of issuance costs of $418,390. The Series B Preferred Stock ranks pari passu in all respects to Enumeral's Series A-2, Series A-1 and Series A Preferred Stock. In connection with the offering, Enumeral compensated the placement agent through the payment of $81,000 and the issuance of a warrant with respect to 38,259 Series B shares exercisable at $2.125 per share for a term of five years. These costs were included in the total issuance costs. All shares and warrants were converted as part of the Merger (see Merger discussion below).
	In April 2014, Enumeral issued warrants to two executive officers to purchase 105,881 shares of Convertible Preferred Series B shares in connection with Enumeral's Series B financing. These warrants were issued in relation to these executives taking a salary reduction prior to the Series B round of financing. In connection with the Merger in July 2014, these warrants were converted into warrants to purchase 309,967 shares of the Company's common stock (see Merger discussion below).
	On July 31, 2014, Enumeral entered into the Merger Agreement, pursuant to which Enumeral became a wholly owned subsidiary of the Company. The Company's authorized capital stock currently consists of 300,000,000 shares of common stock, par value $0.001, and 10,000,000 shares of “blank check” preferred stock, par value $0.001.
	Merger
	As a result of the Merger, all issued and outstanding common and preferred shares of Enumeral were exchanged for common shares of the Company as follows: (a) each share of Enumeral's common stock issued and outstanding immediately prior to the closing of the Merger was converted into 1.102121 shares of the Company's common stock for a total of 4,940,744 shares post-Merger, (b) each share of Enumeral's Series A Preferred Stock issued and outstanding immediately prior to the closing of the Merger was converted into 1.598075 shares of the Company's common stock for a total of 4,421,744 shares post-Merger, (c) each share of Enumeral's Series A-1 Preferred Stock issued and outstanding immediately prior to the closing of the Merger was converted into 1.790947 shares of the Company's common stock for a total of 3,666,428 shares post-Merger, (d) each share of Enumeral's Series A-2 Preferred Stock issued and outstanding immediately prior to the closing of the Merger was converted into 1.997594 shares of the Company's common stock for a total of 3,663,177 shares post-Merger, (e) each share of Enumeral's Series B Preferred Stock issued and outstanding immediately prior to the closing of the Merger was converted into 2.927509 shares of the Company's common stock for a total of 2,777,687 shares post-Merger and (f) a convertible note and accrued interest was converted into 3,230,869 shares of the Company's common stock post-Merger.
	As a result of the Merger and Split-Off, the Company discontinued its pre-Merger business and acquired the business of Enumeral, and will continue the existing business operations of Enumeral as a publicly-traded company under the name Enumeral Biomedical Holdings, Inc. In accordance with “reverse merger” accounting treatment, historical financial statements for Enumeral Biomedical Holdings Inc. as of period ends, and for periods ended, prior to the Merger will be replaced with the historical financial statements of Enumeral prior to the Merger in all future filings with the SEC.
	Private Placement
	On July 31, 2014, the Company closed a private placement offering (the “PPO”) of 21,549,510 units of securities, at a purchase price of $1.00 per unit, each unit consisting of one share of the Company's common stock and a warrant to purchase one share of the Company's common stock at an exercise price of $2.00 per share with a term of five years (the “PPO Warrants”). The investors in the PPO (for so long as they hold shares of the Company's common stock) have anti-dilution protection on those Units purchased in the PPO and not subsequently transferred or sold (other than transfers to trusts or affiliates of such investors for the purpose of estate planning), such that if within two years after the final closing of the PPO the Company shall issue additional shares of the Company's common stock or common stock equivalents (subject to customary exceptions, including but not limited to (a) issuances of awards under the Company's 2014 Equity Incentive Plan and (b) other exempt securities) for a consideration per share less than $1.00 (the “Lower Price”), each such investor would be entitled to receive from the Company additional Units in an amount such that, when added to the number of Units initially purchased by such investor, would equal the number of Units that such investor's PPO subscription amount would have purchased at the Lower Price. The net proceeds received from the PPO were $18,255,448.
	The Company agreed to pay the placement agents in the offering, registered broker-dealers, a cash commission of 10% of the gross funds raised from investors in the PPO. In addition, the placement agents received warrants exercisable for a period of five years to purchase a number of shares of the Company's common stock equal to 10% of the number of shares of common stock with a per share exercise price of $1.00 (the “Agent Warrants”); provided, however, that the placement agents were not entitled to any warrants on the sale of Units in excess of 20,000,000. Any sub-agent of the placement agents that introduced investors to the PPO was entitled to share in the cash fees and warrants attributable to those investors as described above. The Company was also required to reimburse the placement agents $30,000 in the aggregate for legal expenses incurred by the placement agents' counsels in connection with the PPO, as described in the private placement agreements. As a result of the foregoing, the placement agents were paid an aggregate cash commission of $2,154,951 and were issued Agent Warrants to purchase 2,000,000 shares of the Company's common stock. The Agent Warrants not subsequently transferred or sold (other than transfers to trusts or affiliates of such investors for the purpose of estate planning) have “weighted average” anti-dilution protection for the same period as the Units, subject to customary exceptions. The value ascribed to the Agent Warrants are carried at fair value and reported as a derivative liability on the accompanying balance sheets.
	The Company incurred approximately $500,000 of expenses in connection with the offering outside of the placement agent commissions and issued the subagent to one of the placement agents 150,000 shares of the Company's common stock.
	In addition, the Merger Agreement provided certain anti-dilution protection to the holders of the Company's common stock immediately prior to the Merger (after giving effect to the Split-Off), in the event that the aggregate number of units sold in the PPO after the final closing thereof were to exceed 15,000,000. Accordingly, based on the final amount of gross proceeds raised in the PPO, the Company issued 1,693,747 additional shares of the Company's common stock to holders of the Company's common stock immediately prior to the Merger. The Company recorded $1,693,747 in other expense related to this issuance of shares at $1.00 per share.

STOCK_OPTIONS_RESTRICTED_STOCK

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS	9 Months Ended
	Sep. 30, 2014
STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS [Abstract]	'
STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS	'
	9 - STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS
	Stock Options
	In December 2009, Enumeral adopted the 2009 Stock Incentive Plan (the “2009 Plan”). In April 2014, Enumeral amended the 2009 Plan to increase the number of shares authorized thereunder to 3,200,437. The 2009 Plan was terminated in July 2014 in connection with the Merger.
	On July 31, 2014, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2014 Equity Incentive Plan (the “2014 Plan”), which reserves a total of 8,100,000 shares of the Company's common stock for incentive awards. In connection with the Merger, options to purchase 948,567 shares of Enumeral common stock previously granted under the 2009 Plan were converted into options to purchase 1,045,419 shares of the Company's common stock under the 2014 Plan.
	Generally, shares that are expired, terminated, surrendered or cancelled without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.
	As of September 30, 2014, there are 5,724,753 shares available for issuance under the 2014 Plan to eligible employees, nonemployees directors and consultants. This number is subject to adjustment in the event of a stock split, reverse stock split, stock dividend, or other change in the Company's capitalization.
	During the nine months ended September 30, 2014, there were 1,512,630 stock options granted to employees or directors under the 2014 Plan. The vesting of employee and director awards is time-based and the restrictions typically lapse 25% after 12 months and monthly thereafter for the next 36 months for employees and annually over three years for directors. In addition, certain option awards for employees provide for vesting of all or a portion of the shares underlying such option upon the achievement of certain milestones or performance-based criteria. The weighted average, stock price, risk-free interest rate, expected dividend yield, expected term, volatility and grant date fair value of these options granted during the nine months ended September 30, 2014 was $1.00, 2.48%, 0%, 6 years, 105.4%, and $0.82, respectively.
	In July 2014, Enumeral modified the option grants to two former directors of Enumeral. As a result of this modification, 77,148 shares became fully vested and the Company incurred stock based compensation of $63,262 during the three month period ended September 30, 2014.
	Stock option expense for employees was $229,571 and $15,816 for the nine months ended September 30, 2014 and 2013, respectively, while non-employee stock option expense was $5,104 and $3,211 for the nine months ended September 30, 2014 and 2013, respectively. Stock option expense for employees was $220,123 and $7,163 for the three months ended September 30, 2014 and 2013, respectively, while non-employee stock option expense was $2,873 and $1,788 for the three months ended September 30, 2014 and 2013, respectively.
	A summary stock option activity for the nine months ended September 30, 2014 is as follows:
									Weighted-
						Weighted-			Average
						Average			Remaining
						Exercise			Contractual
		Shares				Price			Term (years)
	Outstanding at December 31, 2013		874,056			$	0.22		7.7
	Granted		1,512,630			$	1
	Exercised		-			$	-
	Canceled		(12,266	)		$	1
	Outstanding at September 30, 2014		2,374,420			$	0.71		8.5
	Exercisable at September 30, 2014		677,243			$	0.33		7.2
	The aggregate intrinsic value of options exercisable at September 30, 2014 was $451,487. The aggregate intrinsic value was calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock as of the balance sheet date.
	Restricted Stock
	Restricted stock expense was $149,623 and $104,852 for the nine months ended September 30, 2014 and 2013, respectively, and $12,282 and $34,945 for the three months ended September 30, 2014 and 2013, respectively.
	A summary of restricted stock activity for the nine months ended September 30, 2014 is as follows:
						Weighted-
		Number of				Average Grant
		Shares				Date Fair Value
	Balance of unvested restricted stock at December 31, 2013		1,113,048		$			0.23
	Issuance of restricted stock		-		$			-
	Vested		(716,591	)	$			-0.22
	Balance of unvested restricted stock at September 30, 2014		396,457		$			0.25
	Warrants
	As of September 30, 2014, there are a total of 24,803,409 warrants outstanding to purchase shares of the Company's common stock. Of these, 23,549,510 warrants issued in connection with the PPO and 66,574 warrants issued to Square 1 Bank are accounted for as derivative liability warrants.
	Derivative Liability Warrants
	In connection with the PPO, the Company issued warrants to purchase an aggregate of 23,549,510 shares of the Company's common stock. Additionally, in connection with the Square 1 Financing, Enumeral issued warrants to purchase 41,659 shares of Enumeral's Series A preferred stock that were subsequently converted into warrants to purchase 66,574 shares of the Company's common stock in connection with the July 2014 Merger.
	A) PPO and Agent Warrants
	In July 2014, the Company issued warrants to purchase 23,549,510 shares of the Company's common stock in connection with the PPO, of which warrants to purchase 21,549,510 shares of the Company's common stock had an exercise price of $2.00 per share and were issued to the investors in the PPO, and warrants to purchase 2,000,000 shares of the Company's common stock had an exercise price of $1.00 per share and were issued to the placement agents for the PPO (or their affiliates). All 23,549,510 warrants were outstanding as of September 30, 2014. The estimated fair value of the warrants at the time of issuance was determined to be $16,261,784 using the Black-Scholes pricing model and the following assumptions: expected term of five years, 105.4% volatility, and a risk-free rate of 1.77%. The fair value of the warrants is estimated using a Black-Scholes model. Due to a price protection provision included in the warrant agreements, the warrants were deemed to be a liability and, therefore, the fair value of the warrants is recorded in the liability section of the balance sheet. As such, the outstanding warrants are revalued each reporting period with the resulting gains and losses recorded as the change in fair value of warrant liability on the statement of operations.
	B) Square 1 Financing
	In connection with the December 2011 Square 1 Financing, Enumeral issued to Square 1 Bank warrants to purchase an aggregate of 33,944 shares of Series A convertible preferred stock at an exercise price of $1.16 per share, exercisable for seven years. In July 2014, as part of the Merger, these warrants were converted into a warrant to purchase 54,245 shares of the Company's common stock at an exercise price of $0.73 per share. The estimated fair value of the warrants as of December 31, 2013 was determined to be $33,930 using the Black-Scholes pricing model and the following assumptions: expected term of 4.9 years, 74.3% volatility, and a risk-free rate of 1.75%. As part of a June 12, 2012 amendment to the Loan and Security Agreement between Enumeral and Square 1 Bank, Enumeral issued warrants to Square 1 Bank to purchase an aggregate of 7,715 shares of Series A convertible preferred stock at an exercise price of $1.16 per share, exercisable for seven years. In July 2014, as part of the Merger, these warrants were converted into a warrant to purchase 12,329 shares of the Company's common stock at an exercise price of $0.73 per share. The estimated fair value of these warrants as of December 31, 2013 was determined to be $7,536 using the Black-Scholes pricing model and the following assumptions: expected term of 5.7 years, 74.3% volatility, and a risk-free rate of 1.75%. The warrants are classified as derivative liabilities in the accompanying balance sheets and measured at fair value on a recurring basis. As such, the outstanding warrants are revalued each reporting period with the resulting gains and losses recorded as the change in fair value of warrant liability on the statement of operations. As of September 30, 2014 these warrants are outstanding and expire on December 5, 2018 and June 12, 2019.
	C) Derivative Liability Re-Measurement
	The Company used the Black-Scholes option-pricing model to estimate the fair values of the issued and outstanding warrants as of September 30, 2014 with the following weighted average assumptions: risk-free interest rate of 1.72%, remaining term of 4.83 years, volatility rate of 102.2% and no expected dividends.  As of September 30, 2013, the following weighted average assumptions were used: risk-free interest rate of 1.39%, remaining term of 5.28 years, a volatility rate of 76.1% and no expected dividends.
	The Company recorded expense of $4,833,628 for the nine months ended September 30, 2014 and income of $789 for the nine months ended September 30, 2013, due to the change in the fair value of the warrants. The Company recorded expense of $4,837,307 for the three months ended September 30, 2014 and income of $621 for the three months ended September 30, 2013, due to the change in the fair value of the warrants. Outstanding warrants are revalued each reporting period with the resulting gains and losses recorded as the change in fair value of warrant liability on the statement of operations.
	Other Warrants
	In April 2014, in connection with Enumeral's Series B preferred stock offering, Enumeral compensated the placement agent through the issuance of a warrant with for 38,259 shares of Enumeral Series B preferred stock. The estimated fair value of the warrants at the time of issuance was determined to be $49,854 using the Black-Sholes pricing model and the following assumptions: expected term of five years, 74.6% volatility, and a risk-free rate of 1.72%. The Company recorded this value net against issuance cost in equity. In connection with the Merger in July 2014, these Series B preferred stock warrants were converted into a warrant to purchase 112,001 shares of the Company's common stock.
	In April 2014, Enumeral issued warrants to two executive officers to purchase 105,881 shares of Enumeral Series B preferred stock in connection with Enumeral's Series B financing. These warrants were issued in relation to these executives taking a salary reduction prior to the Series B financing. The estimated fair value of the warrants at the time of issuance was determined to be $137,770 using the Black-Sholes pricing model and the following assumptions: expected term of five years, exercise price of $2.125 per share, 74.6% volatility, and a risk-free rate of 1.63%. This warrant vests over six months. During the three and nine months ended September 30, 2014, the Company recorded $68,885 and $126,289 respectively, of stock based compensation expense related to these grants. In connection with the Merger in July 2014, these Series B warrants were converted into warrants to purchase 309,967 shares of the Company's common stock.
	In April 2014, Enumeral issued warrants associated with Enumeral's convertible promissory notes to purchase 694,443 shares of Enumeral common stock. As part of the Merger, these warrants were converted into warrants to purchase 765,357 shares of the Company's common stock.
	The exercise price of all these warrants is $0.27 per share.

CONCENTRATIONS

CONCENTRATIONS	9 Months Ended
	Sep. 30, 2014
CONCENTRATIONS [Abstract]	'
CONCENTRATIONS	'
	10 - CONCENTRATIONS
	During the nine months ended September 30, 2014, the Company recorded sales to two customers of $75,714 (63%) and $40,000 (33%) in excess of 10% of the Company's total sales. During the nine months ended September 30, 2013, the Company recorded sales to three customers of $182,996 (54%), $89,182 (26%) and $62,500 (18%) in excess of 10% of the Company's total sales. At September 30, 2014, accounts receivable consisted of amounts due from three customers which represented approximately 56%, 36% and 8% of the outstanding accounts receivable balance. At September 30, 2013, accounts receivable consisted of amounts due from three customers which represented approximately 57%, 29% and 14% of the outstanding accounts receivable balance.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	11 - SUBSEQUENT EVENTS
	On November 7, 2014, the Company entered into an Indenture of Lease (the “Lease”) with King 200 CPD LLC (“Landlord”), pursuant to which the Company will lease 16,825 square feet of office and laboratory space located at 200 CambridgePark Drive in Cambridge, Massachusetts (the “Premises”). Under the terms of the Lease, the Company will receive the benefit of a mutually agreed upon “turn-key” build out by Landlord for the Premises.
	The term of the lease (the “Term”) is five years beginning on the Term Commencement Date, which is defined in the Lease as the earlier of (i) substantial completion of certain improvements to the Premises as set forth in the Lease or (ii) the date on which the Company first uses the Premises, or any portion thereof, as permitted pursuant to the provisions of the Lease. Pursuant to the Lease, the Estimated Term Commencement Date is March 15, 2015.
	Pursuant to the terms of the Lease, the initial base rent will be $42.50 per square foot, or approximately $715,062 on an annual basis, which will increase incrementally over the Term, reaching approximately $804,739 on an annual basis in the fifth year of the Term.  In addition, the Company is obligated to pay a proportionate share of the operating expenses and applicable taxes associated with the Premises, as calculated pursuant to the terms of the Lease.  Pursuant to the terms of the Lease, the Company also agreed to deliver to Landlord a security deposit in the approximate amount of $529,699, either in the form of cash or an irrevocable letter of credit, which may be reduced to the approximate amount of $411,988 following the second anniversary of the Term Commencement Date if the Company meets certain financial conditions set forth in the Lease.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	9 Months Ended
	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Recently Adopted Accounting Standards	'
	Recently Adopted Accounting Standards
	On June 10, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) – Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”), which eliminates the concept of a development stage entity in its entirety from current accounting guidance. Amendments to the consolidation guidance may result in more DSEs being considered variable interest entities. The new guidance applies to all entities that previously met the definition of a DSE. ASU 2014-10 is effective for public business entities for annual reporting periods beginning after December 15, 2015, and interim periods therein. Early adoption of the new standard is permitted. Management has elected to early adopt ASU 2014-10, as permitted and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the Company's 2013 financial statements for the year ended December 31, 2013, which are included in the Company's Form 8-K for the Merger occurring on July 31, 2014, as discussed above.
	The preparation of financial statements in conformity with these accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and the reported amounts of expenses during the reported period. Ultimate results could differ from the estimates of management.
	In the opinion of management, the unaudited financial statements included herein contain all adjustments necessary to present fairly the Company's financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September 30, 2014 may not be indicative of results for the full year.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reported period. Significant estimates used in preparing the Company's financial statements include the estimation of stock based compensation, stock warrants liability, accrued expenses, revenue recognition and income taxes. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of 90 days or less from the purchase date to be cash equivalents. Cash and cash equivalents are held in depository and money market accounts and are reported at fair value.
	Marketable securities consist of U.S. treasury securities with maturities of more than 90 days. The Company has determined the appropriate balance sheet classification of the securities as current since they are available for use in current operating activities, regardless of actual maturity dates, and are recorded on the balance sheet at fair value.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	The Company has no significant off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements. Financial instruments that subject the Company to credit risk consists primarily of cash and cash equivalents. The Company generally invests its cash in money market funds, U.S. Treasury securities and U.S. Agency securities that are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. At times, the Company's cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair values of financial instruments included in current assets and current liabilities are estimated to approximate their book values, due to the short maturity of such instruments. All debt was based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value. The Company's assets and liabilities that are measured at fair value on a recurring basis are measured in accordance with FASB's Accounting Standards Codification 820, Fair Value Measurements and Disclosures, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements.
	The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:
		•	Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets in active markets.
		•	Level 2: Inputs to the valuation methodology included quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
		•	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The Company's cash equivalents carried at fair value are primarily comprised of investments in a U.S. Treasury and federal agency backed money market fund. The valuation of the Company's derivative liabilities is discussed below and in Note 9.
	The following table presents information about the Company's financial assets and liabilities measured at a fair value on a recurring basis as of September 30, 2014 and December 31, 2013:
			September 30,		Quoted Prices in		Observable		Unobservable
			2014		Active Markets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets
	Cash		$	1,219,603	$	1,219,603	$	-	$	-
	Money Market funds, included in cash equivalents		$	11,972,281	$	11,972,281	$	-	$	-
	Marketable securities – U.S. Treasuries		$	3,017,324	$	3,017,324	$	-	$	-
	Liabilities
	Derivative liabilities		$	21,136,878	$	-	$	-	$	21,136,878
			December 31,		Quoted Prices		Observable		Unobservable
			2013		in Active		Inputs		Inputs
					Markets		(Level 2)		(Level 3)
					(Level 1)
	Assets
	Cash and cash equivalents		$	263,910	$	263,910	$	-	$	-
	Liabilities
	Derivative liabilities		$	41,466	$	-	$	-	$	41,466
	The following table provides a roll forward of the fair value of the Company's warrant liabilities, using Level 3 inputs:
	Balance at December 31, 2013		$	41,466
	Warrants granted with PPO at July 31, 2014			16,261,784
	Change in fair value			4,833,628
	Balance at September 30, 2014		$	21,136,878
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Trade receivables are recorded at the invoiced amount. The Company maintains allowances for doubtful accounts, if needed, for estimated losses resulting from the inability of customers to make required payments. This allowance is based on specific customer account reviews and historical collections experience. There was no allowance for doubtful accounts as of September 30, 2014 or December 31, 2013.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to expense as incurred, whereas major betterments are capitalized as additions to property and equipment. Depreciation is provided using the straight-line method over the estimated useful lives of the assets as follows:
	Lab equipment		5 years
	Computer equipment and software		3 years
	Furniture		3 years
	Leasehold improvements		Shorter of useful life or life of the lease
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	Long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicated that there is impairment, the amount of the impairment is calculated as the difference between the carrying value and fair value. There have been no impairments recognized during the nine months ended September 30, 2014 and 2013, respectively.
Revenue Recognition - Collaboration and license revenue	'
	Collaboration and license revenue
	Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured and the Company has no further performance obligations under the license agreement. Multiple element arrangements, such as license and development arrangements are analyzed to determine whether the deliverables, which often include license and performance obligations such as research and steering committee services, can be separated or whether they must be accounted for as a single unit of accounting in accordance with GAAP. The Company recognizes up-front license payments as revenue upon delivery of the license only if the license has stand-alone value and the fair value of the undelivered performance obligations, typically including research and/or steering committee services, can be determined. If the fair value of the undelivered performance obligations can be determined, such obligations would then be accounted for separately as performed. If the license is considered to either (i) not have stand-alone or (ii) have stand-alone value but the fair value of any of the undelivered performance obligations cannot be determined, the arrangement would then be accounted for as a single unit of accounting and the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed.
	Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized. Revenue will be recognized using either a relative performance or straight-line method. The Company recognizes revenue using the relative performance method provided that the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and such performance obligations are provided on a best-efforts basis. Direct labor hours or full-time equivalents are typically used as a measure of performance. Revenue recognized under the relative performance method would be determined by multiplying the total payments under the contract, excluding royalties and payments contingent upon achievement of substantive milestones, by the ratio of level of effort incurred to date to estimated total level of effort required to complete the Company's performance obligations under the arrangement. Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the relative performance method, as of each reporting period.
	If the Company cannot reasonably estimate the level of effort required to complete its performance obligations under an arrangement, the performance obligations are provided on best-efforts basis and the Company can reasonably estimate when the performance obligation ceases or the remaining obligations become inconsequential and perfunctory. At that time, the total payments under the arrangement, excluding royalties and payments contingent upon achievement of substantive milestones, would be recognized as revenue on a straight-line basis over a period the Company expects to complete its performance obligations.
	Revenue is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line basis, as of the period ending date.
	The difference between the total consideration received to date and the revenue recognized is recorded as deferred collaboration revenue and totals $0 and $25,714 at September 30, 2014 and December 31, 2013, respectively.
Revenue Recognition - Grant Revenue	'
	Grant Revenue
	The Company recognizes nonrefundable grant revenue that is earned in connection with its Research Agreement with the National Cancer Institute (“NCI”). Grant revenue consists of a portion of the funds received to date by the NCI, which allow the Company to conduct research on colon cancer tissues. Revenue is recognized as the related research services are performed in accordance with the terms of the agreement. The difference between the total consideration received to date and the revenue recognized is recorded as deferred grant revenue and totals $0 at both September 30, 2014 and December 31, 2013. In September 2014, the Company was awarded a Phase II Small Business Innovation Research contract from NCI.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development expenditures are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, clinical supply costs, contract services, depreciation and amortization expense and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred. Legal fees incurred in connection with patent applications, along with fees associated with the license to the Company's core technology, are expensed as research and development expense.
Derivative Liabilities	'
	Derivative Liabilities
	The Company's derivative liabilities relates to (a) warrants to purchase an aggregate of 23,549,510 shares of the Company's common stock that were issued in connection with the July 2014 PPO (as defined below in Note 8) and (b) warrants to purchase 41,659 shares of Enumeral Series A Preferred Stock that were issued in December 2011 and June 2012 pursuant to Enumeral's debt financing arrangement with Square 1 Bank (as further described in Note 5) that were subsequently converted into warrants to purchase 66,574 shares of the Company's common stock in connection with the July 2014 Merger. Additional detail regarding these warrants can be found in Note 9 below.
	Due to the price protection provision included in the warrant agreements, the warrants were deemed to be liabilities and, therefore, the fair value of the warrants is recorded in the current liability section of the balance sheet. As such, the outstanding warrants are revalued each reporting period with the resulting gains and losses recorded as the change in fair value of warrant liability on the statement of operations.
	The Company used the Black-Scholes option-pricing model to estimate the fair values of the issued and outstanding warrants upon issuance and as of September 30, 2014.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company has elected to use the Black-Scholes option pricing model to determine the grant date fair value of share-based awards. The Company recognizes the compensation cost of employee share-based awards on a straight-line basis over the employee's requisite service period of each award, which is generally the vesting period.
	The fair value of the restricted stock awards granted to employees is based upon the fair value of the common stock on the date of grant. Expense is recognized over the vesting period.
	The Company has recorded stock-based compensation expense of $510,587 and $159,754 for the nine months ended September 30, 2014 and 2013, respectively, and $304,163 and $79,771 for three months ended September 30, 2014 and 2013, respectively. The Company has an aggregate of $953,653 of unrecognized stock-based compensation cost as of September 30, 2014 to be amortized over a weighted average period of 1.72 years.
	Prior to the Merger, Enumeral engaged a third party to develop an estimate of the fair value of a share of Enumeral's common stock on a fully-diluted, minority, non-marketable basis as of December 31, 2013. Based upon unaudited historical, pro-forma and/or forecast financial and operational information, which Enumeral management represented as accurately reflecting the company's operating results and financial position, the third party utilized both a market approach (using various financial statement metrics of similar enterprises' equity securities to estimate the fair value of Enumeral's equity securities) and an income approach (which bases value on expectations of future income and cash flows) in their analyses. The fair value of a single share of common stock was determined using the option pricing method, which treats common and preferred stock as call options on the aggregate enterprise value and using traditional models, including Black-Scholes or binomial models, to calculate share values.
	During the quarter ended September 30, 2014, the Company engaged a third party to develop a binomial lattice model to estimate the fair value of options to purchase a total of 450,000 shares with vesting based on the future performance of a share of the Company's common stock.
	Following the Merger, the Company's common stock became publicly traded, and fair market value is determined based on the closing sales price of the Company's common stock on the OTC Markets.
Earnings (Loss) Per Share	'
	Earnings (Loss) Per Share
	Basic earnings (loss) per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of September 30, 2014 and December 31, 2013. At September 30, 2014 and December 31, 2013, the number of shares underlying options and warrants that were anti-dilutive was approximately 27.2 million shares and 0.9 million shares, respectively.
Income Taxes	'
	Income Taxes
	The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company's financial statements contain certain deferred tax assets, which have arisen primarily as a result of operating losses, as well as other temporary differences between financial and tax accounting. The Company would establish a valuation allowance if the likelihood of realization of the deferred tax assets is reduced based on an evaluation of objective verifiable evidence. Significant management judgment is required in determining the Company's provision for income taxes, the Company's deferred tax assets and liabilities and any valuation allowance recorded against those net deferred assets. The Company evaluates the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized.
	The Company accounts for uncertain tax positions in accordance with GAAP and has no uncertain tax liabilities at September 30, 2014 or December 31, 2013. The guidance requires the Company to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authority. If a tax position meets the more likely than not recognition criteria, the guidance requires the tax position be measured at the largest amount of benefit greater than 50% likely of being realized upon ultimate settlement.
New Accounting Pronouncements	'
	New Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”). ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in ASU 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to illustrate the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization's contracts with customers. ASU 2014-09 is effective retrospectively for fiscal years, and interim periods within those years beginning after December 15, 2016 for public companies and 2017 for non-public entities. Management is evaluating the effect, if any, on the Company's financial position and results of operations.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation – Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for annual periods and interim periods within those periods beginning after December 31, 2015. Earlier adoption is permitted. The Company does not expect the adoption of this guidance will have a significant impact on the Company's consolidated financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The following table presents information about the Company's financial assets and liabilities measured at a fair value on a recurring basis as of September 30, 2014 and December 31, 2013:
		September 30,		Quoted Prices in		Observable		Unobservable
		2014		Active Markets		Inputs		Inputs
				(Level 1)		(Level 2)		(Level 3)
	Assets
	Cash	$	1,219,603	$	1,219,603	$	-	$	-
	Money Market funds, included in cash equivalents	$	11,972,281	$	11,972,281	$	-	$	-
	Marketable securities – U.S. Treasuries	$	3,017,324	$	3,017,324	$	-	$	-
	Liabilities
	Derivative liabilities	$	21,136,878	$	-	$	-	$	21,136,878
		December 31,		Quoted Prices		Observable		Unobservable
		2013		in Active		Inputs		Inputs
				Markets		(Level 2)		(Level 3)
				(Level 1)
	Assets
	Cash and cash equivalents	$	263,910	$	263,910	$	-	$	-
	Liabilities
	Derivative liabilities	$	41,466	$	-	$	-	$	41,466
Schedule of Warrant Liabilities	'
	The following table provides a roll forward of the fair value of the Company's warrant liabilities, using Level 3 inputs:
	Balance at December 31, 2013	$	41,466
	Warrants granted with PPO at July 31, 2014		16,261,784
	Change in fair value		4,833,628
	Balance at September 30, 2014	$	21,136,878
Schedule of Estimated Useful Lives	'
	Lab equipment	5 years
	Computer equipment and software	3 years
	Furniture	3 years
	Leasehold improvements	Shorter of useful life or life of the lease

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2014
PROPERTY AND EQUIPMENT [Abstract]	'
Schedule of Property and Equipment, Net	'
	Property and equipment, net consist of the following:
		September 30,			December 31,
		2014			2013
	Laboratory equipment	$	1,113,513		$	1,082,438
	Computer/office equipment and software		100,655			87,563
	Furniture, fixtures and office equipment		18,772			18,772
	Leasehold improvements		112,507			112,507
			1,345,447			1,301,280
	Less - Accumulated depreciation and amortization		(765,906	)		(553,392	)
		$	579,541		$	747,888

COMMITMENTS_Tables

COMMITMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
COMMITMENTS [Abstract]	'
Schedule of Future Operating Lease Commitments	'
	Future operating lease commitments as of September 30, 2014 are as follows:
	Year Ending December 31,
	2014	$	62,166
	2015		228,919
		$	291,085

STOCK_OPTIONS_RESTRICTED_STOCK1

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2014
STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS [Abstract]	'
Summary of Stock Option Activity	'
									Weighted-
						Weighted-			Average
						Average			Remaining
						Exercise			Contractual
		Shares				Price			Term (years)
	Outstanding at December 31, 2013		874,056			$	0.22		7.7
	Granted		1,512,630			$	1
	Exercised		-			$	-
	Canceled		(12,266	)		$	1
	Outstanding at September 30, 2014		2,374,420			$	0.71		8.5
	Exercisable at September 30, 2014		677,243			$	0.33		7.2
Summary of Restricted Stock Activity	'
						Weighted-
		Number of				Average Grant
		Shares				Date Fair Value
	Balance of unvested restricted stock at December 31, 2013		1,113,048		$			0.23
	Issuance of restricted stock		-		$			-
	Vested		(716,591	)	$			-0.22
	Balance of unvested restricted stock at September 30, 2014		396,457		$			0.25

NATURE_OF_BUSINESS_Details

NATURE OF BUSINESS (Details)	1 Months Ended
	Jul. 31, 2014
NATURE OF BUSINESS [Abstract]	'
Number of shares held by pre-merger majority stockholder cancelled pursuant to the Split-Off Agreement	23,100,000

RISK_AND_UNCERTAINTIES_Details

RISK AND UNCERTAINTIES (Details) (USD $)	1 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
RISK AND UNCERTAINTIES [Abstract]	'	'	'
Working capital	'	$5,454,981	'
Derivative liabilities	'	21,136,878	41,466
Accumulated defict	'	-20,731,634	-9,511,237
Gross proceeds from reverse merger	$21,500,000	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue Recognition	'	'	'	'	'
Deferred collaboration revenue	$0	'	$0	'	$25,714
Grant Revenue	'	'	'	'	'
Deferred grant revenue	0	'	0	'	0
Stock-Based Compensation	'	'	'	'	'
Stock-based compensation expense	304,163	79,771	510,587	159,754	'
Unrecognized stock-based compensation	$953,653	'	$953,653	'	'
Unrecognized stock-based compensation, period for recognition	'	'	'1 year 8 months 19 days	'	'
Options issued during period	450,000	'	'	'	'
Number of shares underlying options and warrants that were anti-dilutive	'	'	27,200,000	'	900,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
Assets	'	'
Cash and cash equivalents	$1,219,603	$263,910
Money Market funds, included in cash equivalents	11,972,281	'
Marketable securities - U.S. Treasuries	3,017,324	'
Liabilities	'	'
Derivative liabilities	21,136,878	41,466
Quoted Prices in Active Markets (Level 1) [Member]	'	'
Assets	'	'
Cash and cash equivalents	1,219,603	263,910
Money Market funds, included in cash equivalents	11,972,281	'
Marketable securities - U.S. Treasuries	3,017,324	'
Liabilities	'	'
Derivative liabilities	'	'
Observable Inputs (Level 2) [Member]	'	'
Assets	'	'
Cash and cash equivalents	'	'
Money Market funds, included in cash equivalents	'	'
Marketable securities - U.S. Treasuries	'	'
Liabilities	'	'
Derivative liabilities	'	'
Unobservable Inputs (Level 3) [Member]	'	'
Assets	'	'
Cash and cash equivalents	'	'
Money Market funds, included in cash equivalents	'	'
Marketable securities - U.S. Treasuries	'	'
Liabilities	'	'
Derivative liabilities	$21,136,878	$41,466

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Warrant Liabilities) (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'	'
Balance at December 31, 2013	'	'	'	$41,466	'
Warrants granted with PPO at July 31, 2014	16,261,784	'	'	'	'
Change in fair value	'	4,837,307	-621	4,833,628	-789
Balance at September 30, 2014	'	$21,136,878	'	$21,136,878	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Estimated Useful Lives) (Details)	9 Months Ended
	Sep. 30, 2014
Lab equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, useful life	'5 years
Computer equipment and software [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, useful life	'3 years
Furniture [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, useful life	'3 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Derivative Liabilities) (Details)	Sep. 30, 2014	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2014
	Square 1 Bank [Member]	Private Placement [Member]	Financing and Security Agreement [Member]	Financing and Security Agreement [Member]
		Reverse Merger [Member]		Square 1 Bank [Member]
Class of Warrant or Right [Line Items]	'	'	'	'
Number of shares callable from warrants	66,574	23,549,510	41,659	66,574

PROPERTY_AND_EQUIPMENT_Narrati

PROPERTY AND EQUIPMENT (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
PROPERTY AND EQUIPMENT [Abstract]	'	'	'	'
Depreciation and amortization	$70,985	$71,752	$212,514	$209,147

PROPERTY_AND_EQUIPMENT_Schedul

PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Cost	$1,345,447	$1,301,280
Less - Accumulated depreciation and amortization	-765,906	-553,392
Property and equipment, net	579,541	747,888
Lab equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	1,113,513	1,082,438
Computer equipment and software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	100,655	87,563
Furniture [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	18,772	18,772
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	$112,507	$112,507

DEBT_Narrative_Details

DEBT (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2011

Feb. 28, 2014

Sep. 30, 2014

Dec. 31, 2011

Sep. 30, 2014

Jul. 31, 2014

Feb. 28, 2014

Sep. 30, 2014

Square 1 Bank [Member]

Square 1 Bank [Member]

Term Loan B [Member]

Financing and Security Agreement [Member]

Financing and Security Agreement [Member]

Financing and Security Agreement [Member]

Financing and Security Agreement [Member]

Convertible Promissory Notes [Member]

Convertible Promissory Notes [Member]

Convertible Promissory Notes [Member]

Square 1 Bank [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

'

'

'

$1,790,000

'

'

$750,000

'

Accrued interest

'

'

'

'

'

'

'

'

'

'

'

41,500

'

'

Shares issued in conversion of convertible promissory notes

'

'

3,230,869

'

'

'

'

'

'

'

'

3,230,869

'

'

Total gross cash proceeds under equity financing agreement required as of March 31, 2014

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

Total gross cash proceeds under equity financing agreement required as of June 30, 2014

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

Amended date of when the gross proceeds under the equity financing agreement must be raised

'

'

'

'

'

'

'

'

1-Aug-14

'

'

'

'

'

Monthly minimum unrestricted cash balance required by bank as part of loan and security agreement

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

Equity financing milestone

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

Number of shares callable from warrants

'

'

'

'

66,574

'

'

'

41,659

'

66,574

'

'

'

Interest per annum

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

Maturity date

'

'

'

'

'

'

'

'

'

'

'

'

31-Jul-15

'

Conversion price

'

'

'

'

'

'

'

'

'

'

'

'

$0.27

'

Debt discount

'

'

'

'

'

'

'

'

'

'

'

103,846

140,779

'

Fair value of warrants

'

'

'

'

'

7,536

'

'

'

'

'

'

140,778

'

Adjusted conversion price

'

'

'

'

'

'

'

'

'

'

'

'

$0.22

'

Estimated fair value of Company's common stock per share

'

'

'

'

'

'

'

'

'

'

'

'

$0.27

'

Interest expense

$140,917

$25,145

$268,998

$84,077

'

'

'

'

'

'

'

'

'

$177,712

COMMITMENTS_Details

COMMITMENTS (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Nov. 07, 2014	Sep. 30, 2014
					Office Lease Two - Cambridge, Massachusetts	Office Lease Two - Cambridge, Massachusetts [Member]
					Subsequent Event [Member]	sqft
					sqft
Operating Leased Assets [Line Items]	'	'	'	'	'	'
Lease term	'	'	'	'	'5 years	'37 months
Square footage of leased property	'	'	'	'	16,825	4,782
Lease expiration date	'	'	'	'	'	30-Nov-15
Rent expense	$78,017	$75,544	$231,084	$216,778	'	'
Future operating lease commitments:	'	'	'	'	'	'
2014	62,166	'	62,166	'	'	'
2015	228,919	'	228,919	'	'	'
Total future minimum payments due	$291,085	'	$291,085	'	'	'

LICENSE_AGREEMENT_AND_RELATEDP1

LICENSE AGREEMENT AND RELATED-PARTY TRANSACTIONS (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Apr. 30, 2011

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2011

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Apr. 30, 2011

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Aug. 14, 2013

Feb. 11, 2013

Apr. 19, 2011

Apr. 30, 2011

Apr. 30, 2011

Apr. 30, 2011

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

License Agreement [Member]

License Agreement [Member]

MIT [Member]

MIT [Member]

MIT [Member]

MIT [Member]

MIT [Member]

Harvard [Member]

Harvard [Member]

Harvard [Member]

Harvard [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Allan Rothstein and Norman Rothstein [Member]

Allan Rothstein and Norman Rothstein [Member]

Allan Rothstein and Norman Rothstein [Member]

Allan Rothstein and Norman Rothstein [Member]

Barry Buckland PhD [Member]

Barry Buckland PhD [Member]

Barry Buckland PhD [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

Restricted common stock [Member]

Restricted common stock [Member]

Restricted common stock [Member]

Restricted common stock [Member]

Restricted common stock [Member]

SAB Agreement

SAB Agreement

SAB Agreement

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Award, Tranche Two [Member]

Monthly through April 1, 2014 [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development

$1,058,711

$583,372

$2,535,228

$1,749,775

'

'

$6,250

$5,041

$18,750

$14,959

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty and milestone payments, 2014

'

'

'

'

'

'

25,000

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty and milestone payments, 2015

'

'

'

'

'

'

30,000

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty and milestone payments, 2016

'

'

'

'

'

'

40,000

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty and milestone payments, due every year thereafter

'

'

'

'

'

'

50,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for reimbursements

'

'

'

'

'

'

275,499

8,440

399,388

157,611

'

13,435

9,620

114,217

26,629

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock - license agreement, shares

'

'

'

'

66,303

146,406

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Funding requirement of capital stock

'

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percent of common stock issuable

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for consulting services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,274

35,875

Consulting agreement, shares issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

159,045

'

'

'

'

'

'

'

'

'

'

Issuance of restricted stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Vesting percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

50.00%

'

'

'

'

'

'

'

Consulting agreement, term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'2 years

'

'

Consulting agreement, payment amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,500

75,000

'

'

'

'

'

'

'

'

100,000

'

'

Consulting agreement expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12,500

$10,827

$15,209

$52,989

'

'

'

'

'

'

'

$0

$68,764

'

'

'

'

EQUITY_Common_Stock_Details

EQUITY (Common Stock) (Details) (USD $)	Sep. 30, 2014	Apr. 08, 2014	Apr. 07, 2014	Dec. 31, 2013	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Jul. 31, 2014
					Placement Agent [Member]	Series B convertible preferred stock [Member]	Series B convertible preferred stock [Member]	Series B convertible preferred stock [Member]	Warrants issued to the executive officers [Member]	Warrants issued to the executive officers [Member]
							Placement Agent [Member]	Two Executive Officers [Member]		Common stock [Member]
Common Stock [line items]	'	'	'	'	'	'	'	'	'	'
Preferred stock, shares issued	0	'	'	0	'	948,823	'	'	'	'
Equity issuance, price per share	'	'	'	'	'	$2.13	'	'	'	'
Proceeds from issuance of convertible preferred stock, net of issuance costs	'	'	'	'	'	$1,597,860	'	'	'	'
Stock issuance costs	'	'	'	'	$81,000	$418,390	'	'	'	'
Number of shares callable from warrants	'	'	'	'	'	'	38,259	105,881	'	309,967
Exercise price of warrants	'	'	'	'	'	'	$2.13	'	$2.13	'
Term of warrants	'	'	'	'	'	'	'5 years	'	'	'
Common stock, shares authorized	300,000,000	24,000,000	15,000,000	300,000,000	'	'	'	'	'	'
Common stock, par value	$0.00	'	'	$0.00	'	'	'	'	'	'
Preferred stock, shares authorized	10,000,000	'	'	10,000,000	'	'	'	'	'	'
Preferred stock, par value	$0.00	'	'	$0.00	'	'	'	'	'	'

EQUITY_Merger_Details

EQUITY (Merger) (Details)	9 Months Ended
	Sep. 30, 2014
Merger [line items]	'
Number of shares issued upon conversion of convertible note and accrued interest	3,230,869
Series A convertible preferred stock [Member]	'
Merger [line items]	'
Conversion ratio	1.598075
Number of shares issued	4,421,744
Series A-1 convertible preferred stock [Member]	'
Merger [line items]	'
Conversion ratio	1.790947
Number of shares issued	3,666,428
Series A-2 convertible preferred stock [Member]	'
Merger [line items]	'
Conversion ratio	1.997594
Number of shares issued	3,663,177
Series B convertible preferred stock [Member]	'
Merger [line items]	'
Conversion ratio	2.927509
Number of shares issued	2,777,687
Common stock [Member]	'
Merger [line items]	'
Conversion ratio	1.102121
Number of shares issued	4,940,744
Number of shares issued upon conversion of convertible note and accrued interest	3,230,869

EQUITY_Private_Placement_Detai

EQUITY (Private Placement) (Details) (Private Placement [Member], USD $)	0 Months Ended
	Jul. 31, 2014
Private Placement [Line Items]	'
Number of units of securities sold	21,549,510
Sales price per unit of securities sold	$1
Number of common shares per unit	1
Number of warrants per unit	1
Exercise price of warrants	$2
Term of warrants	'5 years
Holding term in which additional shares are issued to the holder	'2 years
Maximum price of additional shares issued	$1
Proceeds received through private placement	$18,255,448
Commission rate paid to placement agents expressed as a percentage of the gross funds raised from investors in the PPO	10.00%
Maximum number of unit sales that agents are entitled to receive warrant commissions	20,000,000
Aggregate legal expenses that are reimbursable to placement agents in connection with private placement offering	30,000
Proceeds received through private placement	500,000
The maximum number of units that can be sold through private placement inorder to provide certain anti-dilution protection to the holders of the Company's Common Stock immediately prior to the Merger (after giving effect to the Split-Off)	15,000,000
Placement Agent [Member]	'
Private Placement [Line Items]	'
Exercise price of warrants	$1
Term of warrants	'5 years
Payments for commissions	2,154,951
Number of common shares issued from warrants provided to placement agents	2,000,000
Stock issued during period, shares	150,000
Holders of Company's Common Stock [Member]	'
Private Placement [Line Items]	'
Stock issued during period, shares	1,693,747
Issuance cost	$1,693,747
Equity issuance, price per share	$1

STOCK_OPTIONS_RESTRICTED_STOCK2

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Stock Options Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Jul. 31, 2014

Apr. 30, 2014

Jul. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Employee [Member]

Employee [Member]

Employee [Member]

Employee [Member]

Director [Member]

Employee And Director [Member]

Non-employee [Member]

Non-employee [Member]

Non-employee [Member]

Non-employee [Member]

Two Executive Officers [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2014 Equity Incentive Plan [Member]

2014 Equity Incentive Plan [Member]

2014 Equity Incentive Plan [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Common Stock [Member]

Common Stock [Member]

Employee And Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares reserved for issuance under the plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,200,437

8,100,000

'

'

Options to purchase shares of common stock

2,374,420

'

2,374,420

'

874,056

'

'

'

'

'

'

'

'

'

'

'

948,567

'

1,045,419

'

'

Number of options granted during period

'

'

1,512,630

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,512,630

Number of shares available for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,724,753

'

Vesting period

'

'

'

'

'

'

'

'36 months

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

$304,163

$79,771

$510,587

$159,754

'

$220,123

$7,163

$229,571

$15,816

'

'

$2,873

$1,788

$5,104

$3,211

$63,262

'

'

'

'

'

Weighted average, stock price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate (as a percent)

'

'

1.72%

1.39%

'

'

'

'

'

'

2.48%

'

'

'

'

'

'

'

'

'

'

Expected dividend yield (as a percent)

'

'

0.00%

0.00%

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

Expected term

'

'

'4 years 9 months 29 days

'5 years 3 months 11 days

'

'

'

'

'

'

'6 years

'

'

'

'

'

'

'

'

'

'

Volatility rate (as a percent)

'

'

102.20%

76.10%

'

'

'

'

'

'

105.40%

'

'

'

'

'

'

'

'

'

'

Grant date fair value of options granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$0.82

'

'

'

'

'

'

'

'

'

'

Number of shares vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

77,148

'

'

'

'

'

Intrinsic value of stock options exercisable

$451,487

'

$451,487

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCK_OPTIONS_RESTRICTED_STOCK3

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Shares:	'	'
Options outstanding at beginning of period	874,056	'
Granted	1,512,630	'
Exercised	'	'
Canceled	-12,266	'
Options outstanding at end of period	2,374,420	874,056
Options exercisable at end of period	677,243	'
Weighted average exercise price per share:	'	'
Options outstanding at beginning of period	$0.22	'
Granted	$1	'
Exercised	'	'
Canceled	$1	'
Options outstanding at end of period	$0.71	$0.22
Options exercisable at end of period	$0.33	'
Weighted Average Remaining Contractual Term	'	'
Options outstanding at beginning of period	'8 years 6 months	'7 years 8 months 12 days
Options outstanding at end of period	'8 years 6 months	'7 years 8 months 12 days
Options exercisable at end of period	'7 years 2 months 12 days	'

STOCK_OPTIONS_RESTRICTED_STOCK4

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Restricted Stock Narrative) (Details) (Restricted Stock [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restricted Stock [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted stock expense	$12,282	$34,945	$149,623	$104,852

STOCK_OPTIONS_RESTRICTED_STOCK5

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Summary of Restricted Stock Activity) (Details) (Restricted Stock [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Restricted Stock [Member]	'
Number of shares:	'
Balance of unvested restricted stock, beginning of period	1,113,048
Issuance of restricted stock	'
Vested	-716,591
Balance of unvested restricted stock, end of period	396,457
Weighted Average Grant Date Fair Value:	'
Balance of unvested restricted stock, beginning of period	$0.23
Issuance of restricted stock	'
Vested	($0.22)
Balance of unvested restricted stock, end of period	$0.25

STOCK_OPTIONS_RESTRICTED_STOCK6

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Details 1) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jul. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jul. 31, 2014

Jun. 30, 2012

Sep. 30, 2014

Jun. 12, 2012

Dec. 31, 2011

Jul. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Apr. 30, 2014

Apr. 30, 2014

Jul. 31, 2014

Apr. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Jul. 31, 2014

Apr. 30, 2014

Apr. 30, 2014

Financing And Security Agreement [Member]

Square 1 Bank [Member]

Square 1 Bank [Member]

Square 1 Bank [Member]

Square 1 Bank [Member]

Square 1 Bank [Member]

Lender [Member].

Lender [Member].

Lender [Member].

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

PPO and Agent Warrants [Member]

PPO and Agent Warrants [Member]

Warrants issued to the investors in the PPO [Member]

Warrants issued to the placement agents in the PPO [Member]

Warrants issued to the placement agents [Member]

Warrants issued to the placement agents [Member]

Warrants issued to the placement agents [Member]

Warrants issued to the executive officers [Member]

Warrants issued to the executive officers [Member]

Warrants issued to the executive officers [Member]

Warrants issued to the executive officers [Member]

Warrants issued to the executive officers [Member]

Warrants associated with convertible promissory notes

Warrants associated with convertible promissory notes

Warrant [Member]

Warrant [Member]

Financing And Security Agreement [Member]

Warrant [Member]

Warrant [Member]

Square 1 Bank [Member]

Square 1 Bank [Member]

Square 1 Bank [Member]

Lender [Member].

Series B Preferred Stock [Member]

Common Stock [Member]

item

Series B Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase shares of the common stock issued

'

'

'

41,659

66,574

'

'

12,329

66,574

'

'

54,245

'

41,659

7,715

33,944

'

23,549,510

21,549,510

2,000,000

'

38,259

112,001

'

'

'

105,881

309,967

694,443

765,357

Exercise price of warrants

'

'

'

'

'

'

'

$0.73

'

'

'

$0.73

'

'

$1.16

$1.16

'

'

$2

$1

'

'

'

$2.13

'

'

'

'

$0.27

'

Term of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

24,803,409

24,803,409

'

'

66,574

'

'

'

'

'

'

'

'

'

'

'

23,549,510

23,549,510

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants

'

'

'

'

'

$7,536

'

'

'

$33,930

'

'

'

'

'

'

$16,261,784

'

'

'

$49,854

'

'

$137,770

'

'

'

'

'

'

Expected term

'

'4 years 9 months 29 days

'5 years 3 months 11 days

'

'

'

'5 years 8 months 12 days

'

'

'

'4 years 10 months 24 days

'

'

'

'

'

'5 years

'

'

'

'5 years

'

'

'5 years

'

'

'

'

'

'

Volatility rate

'

102.20%

76.10%

'

'

'

74.30%

'

'

'

74.30%

'

'

'

'

'

105.40%

'

'

'

74.60%

'

'

74.60%

'

'

'

'

'

'

Risk-free interest rate

'

1.72%

1.39%

'

'

'

1.75%

'

'

'

1.75%

'

'

'

'

'

1.77%

'

'

'

1.72%

'

'

1.63%

'

'

'

'

'

'

Expected dividend

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expense recorded due to the change in the fair value of the warrants

4,837,307

4,833,628

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income recorded due to the change in the fair value of the warrants

621

789

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of executive officers to whom warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

Stock based compensation expense

'

$510,587

$159,754

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$68,885

$126,289

'

'

'

'

CONCENTRATIONS_Details

CONCENTRATIONS (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Concentration Risk [Line Items]	'	'	'	'
Revenues	$70,408	$140,840	$121,122	$341,044
Accounts Receivable [Member] | Major Customer One [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage	'	'	56.00%	57.00%
Accounts Receivable [Member] | Major Customer Two [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage	'	'	36.00%	29.00%
Accounts Receivable [Member] | Major Customer Three [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage	'	'	8.00%	14.00%
Revenue [Member] | Major Customer One [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage	'	'	63.00%	54.00%
Revenues	'	'	75,714	182,996
Revenue [Member] | Major Customer Two [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage	'	'	33.00%	26.00%
Revenues	'	'	40,000	89,182
Revenue [Member] | Major Customer Three [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk percentage	'	'	'	18.00%
Revenues	'	'	'	$62,500

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], King 200 CPD LLC [Member], USD $)	0 Months Ended
	Nov. 07, 2014
	sqft
Subsequent Event [Member] | King 200 CPD LLC [Member]	'
Subsequent Event [Line Items]	'
Office and laboratory space which the Company will lease (in square feet)	16,825
Term of the lease	'5 years
Initial base rent per square foot	$42.50
Initial base rent on an annual basis	715,062
Maximum initial base rent on an annual basis	804,739
Security deposit agreed to delivered to Landlord	529,699
Security Deposit Following Second Anniversary of Term Commencement Date	$411,988